Diagnostics such as c-reactive protein tests are more sensitive than ever before, but manufacturers are still struggling to place them in primary care and community settings where they can make huge differences.

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.

Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics and Medical Devices – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.

In a discussion with Medtech Insight, analysts at Ladenburg Thalmann argued the case for their LumiraDX $14.75 price target.